Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI354 in HER2-positive advanced breast cancer
NCT07377643Phase 3Recruiting
- Sponsor
- Innovent Biologics
- Start
- Feb 2026
- Primary completion
- Apr 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 3 trial of IBI354 in HER2-positive breast cancer, sponsored by Innovent Biologics. Started Feb 2026; status: recruiting.
02
Drugs
IBI354
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT07377643.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07377643.